Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

Cancer is not a welcome diagnosis, but breakthroughs in genetic sequencing and immunotherapy are making some cancers easier ...

Scientists have identified a protein tied to Alzheimer’s that enables lung cancer to spread to the brain, paving the way for ...

The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

BrightSpring Health Services Inc. (NASDAQ:BTSG) is one of the best new stocks to buy now. On June 18, BrightSpring Health ...

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell ...

CHEST guideline updates support minimally invasive resection and targeted therapy to enhance survival in Stage I–II NSCLC.

The FDA has granted accelerated approval to datopotamab deruxtecan (Datroway) for adults with locally advanced or metastatic non-small cell lung cancer that carries an EGFR mutation and has progressed ...

Results of a meta-analysis suggest that ctDNA positivity is a “biomarker for poor postoperative recurrence and survival outcomes in NSCLC patients,” researchers wrote.